用于超长股腘动脉粥样硬化病变（> 30厘米）的紫杉醇涂层球囊血管成形术：来自单一中心的12个月结果
Paclitaxel-coated balloons angioplasties for extra-long femoropopliteal artery atherosclerotic lesions (> 30 cm):12 months outcomes from a single center.
作者信息
Pan Tao, Zhang Guodong, Liu Zhen, Zhang Tao, Li Cheng, Ji Donghua
机构信息
The Interventional Therapy Department of the First Affiliated Hospital of Dalian Medical University, Dalian, 116011, China.
出版信息
J Interv Med. 2022 Feb 26;5(1):28-31. doi: 10.1016/j.jimed.2021.12.005. eCollection 2022 Feb.
OBJECTIVE
To evaluate the efficacy of paclitaxel-coated balloon (PCB) in the treatment of extra-long femoropopliteal artery atherosclerotic disease (>30 cm).
MATERIALS AND METHODS
Forty-nine patients with extra-long femoropopliteal artery atherosclerotic disease were treated with PCB alone in a single center from July 2016 to May 2018. Primary patency and freedom from clinically driven target lesion revascularization (FF-CDTLR) rates during 12 months were analyzed retrospectively.
RESULTS
All patients were followed up for 18.2 ± 7.5 months, and the mean treated lesion length was 34.9 ± 3.7 cm. The primary patency rates were 87.8% (43/49) and 71.4% (35/49) at 6 and 12 months, respectively. FF-CDTLR was 91.8% (45/49) and 77.6% (38/49) at 6 and 12 months, respectively. No mortality or amputation occurred in these patients during the follow-up period.
CONCLUSIONS
PCB has favorable clinical efficacy in patients with extra-long femoropopliteal artery atherosclerotic lesions.
目的
评估紫杉醇涂层球囊（PCB）治疗超长股腘动脉粥样硬化疾病（>30厘米）的疗效。
材料与方法
2016年7月至2018年5月，在单一中心对49例超长股腘动脉粥样硬化疾病患者单独使用PCB进行治疗。回顾性分析12个月内的主要通畅率和免于临床驱动的靶病变血运重建（FF-CDTLR）率。
结果
所有患者均随访18.2±7.5个月，平均治疗病变长度为34.9±3.7厘米。6个月和12个月时的主要通畅率分别为87.8%（43/49）和71.4%（35/49）。6个月和12个月时的FF-CDTLR分别为91.8%（45/49）和77.6%（38/49）。随访期间这些患者未发生死亡或截肢情况。
结论
PCB对超长股腘动脉粥样硬化病变患者具有良好的临床疗效。
Zotero 插件